Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 16,133 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Rosacea
Interventions: DER 45 EV, Vehicle; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Miami, Florida • Augusta, Georgia • Fridley, Minnesota + 6 more

Conditions: Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
Interventions: Purell Hand Sanitizer, Medical Grade Mineral Oil; Drug
Lead sponsor: Leciel Bono; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Pocatello, Idaho • St. George, Utah

Conditions: Urticaria
Interventions: Xolair® (Omalizumab); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lupus Nephritis
Interventions: Rituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine, Acetaminophen, Belimumab; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Marfan Syndrome
Interventions: Losartan Potassium, Atenolol; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 6 Months to 25 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 24
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 18 more

Conditions: Breast Cancer
Interventions: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 30
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more

Conditions: Dupuytren's Contracture
Interventions: collagenase; Drug
Lead sponsor: State University of New York; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2004
U.S. locations: 2
States / cities: Palo Alto, California • Stony Brook, New York

Conditions: Breast Cancer, Fatigue
Interventions: transcranial direct current stimulation, sham transcranial direct current stimulation; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Dupilumab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Herpes Labialis
Interventions: Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more

Conditions: Melanoma (Skin)
Interventions: temsirolimus; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 18
States / cities: Duarte, California • Los Angeles, California • Pasadena, California + 14 more

Conditions: Gynecomastia, Endocrine System Diseases
Interventions: No Intervention; Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 2 Years to 15 Years
Enrollment: 2,000 participants
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Eribulin, Balixafortide; Drug
Lead sponsor: Spexis AG; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 28
States / cities: Fresno, California • Los Angeles, California • San Francisco, California + 23 more

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Natural Killer Cell Therapy, Temozolomide; Biological · Drug
Lead sponsor: Kari Kendra; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Craniofacial Microsomia, Hemifacial Microsomia, Oculo-Auriculo-Vertebral-Syndrome, Goldenhar Syndrome, Microtia
Interventions: Not listed
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 12 Months to 24 Months
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Chapel Hill, North Carolina + 2 more

Conditions: Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions: Santyl, Control; Biological · Procedure
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Phoenix, Arizona • Tucson, Arizona • Southfield, Michigan + 3 more

Conditions: Breast Cancer, Non-small Lung Cancer
Interventions: Docetaxel, GDC-0032, Paclitaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 10
States / cities: Tampa, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more

Conditions: Breast Cancer, Stage IV Breast Cancer
Interventions: positron emission tomography, copper Cu 64-DOTA-trastuzumab, Biopsy, Immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis; Procedure · Radiation · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Mammography, Breast Cancer, Radiology
Interventions: Search only for masses, Search only for calcifications, Search for both together, Search for one after the other; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
Interventions: RP1, intra-tumoral injection, oncolytic virus; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more

Conditions: Breast Cancer
Interventions: mammography; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 311
States / cities: Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more

Conditions: Melanoma
Interventions: Skin Self Examination Information and ABCDE Rule; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 3
States / cities: Chicago, Illinois • Maywood, Illinois • Lebanon, New Hampshire

Conditions: Psoriasis
Interventions: Internet Survey; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 12 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions: Experimental Arm A: Pemetrexed, Experimental Arm A: Sorafenib, Experimental Arm B: Pemetrexed, Experimental Arm B: Sorafenib; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

A Study of DER 45-EV Gel to Treat Rosacea

Hand Sanitizer Use for Herpes Simplex Virus-1

Effect of Anti-IgE in Chronic Urticaria

Rituximab and Belimumab for Lupus Nephritis

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease

Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function

Ethnic Differences in Mechanisms of Action of Dupilumab

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

CCI-779 in Treating Patients With Metastatic Melanoma

Skincare Products and Environmental Health

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)

Using Santyl on Diabetic Foot Ulcers

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

Partner Assistance in Learning and Performing Skin Self-Examination

Oral Psoriasis Treatment Adherence and Intervention Study

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer